Locations:
SearchAdvertisement
Study explores atezolizumab for myelodysplastic syndrome
FDA approval may come in 2019
Lower toxicity than conventional chemo
A closer look at a promising therapy
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Response rates as good as or better than other therapies
New recommendations for second-line therapy
Doctors called to heal, not just treat
Groundbreaking study paves way for targeted therapy
Hope that effective therapies will soon exist for all tumor profiles
Recent survey shows more awareness needed
Advertisement
Advertisement